Literature DB >> 12242655

Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells.

John F Timms1, Sarah L White, Michael J O'Hare, Michael D Waterfield.   

Abstract

Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours overexpress the ErbB-2 receptor. Herein, a non-transformed, immortalized cell system was used to investigate the effects of ErbB-2 overexpression in luminal epithelial cells. The phenotypic consequence of ErbB-2 overexpression is a shortening of the G1 phase of the cell cycle and early S phase entry, which leads to hyperproliferation. We show that this effect was mediated through the up-regulation of cdk6 and cyclins D1 and E, and enhanced degradation and relocalization of p27(Kip1). These changes were effected predominantly through enhanced MAPK signalling, resulting in cdk2 hyperactivation. PI3K signalling also participated in cell cycle progression, since PI3K and MAPK coordinately regulated changes in cyclin D1 and cdk6 expression. Cdk4 activity was not required for cell cycle progression in these cells, and was constitutively inhibited through its association with p16(INK4A). MAPK-dependent induction of p21(Cip1) was also necessary for G1 phase progression, although its degradation by the proteasome was required for S phase entry. These data provide new insights into the complex molecular mechanisms underlying mitogenic cell cycle control in luminal epithelial cells, the cell type relevant to primary breast cancer, and show how ErbB-2 overexpression subverts this normal control.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242655     DOI: 10.1038/sj.onc.1205847

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Growth factor regulation of cell cycle progression in mammary epithelial cells.

Authors:  Malinda A Stull; Anne M Rowzee; Aimee V Loladze; Teresa L Wood
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Platelet-rich plasma increases proliferation of tendon cells by modulating Stat3 and p27 to up-regulate expression of cyclins and cyclin-dependent kinases.

Authors:  T-Y Yu; J-H S Pang; K P-H Wu; L-P Lin; W-C Tseng; W-C Tsai
Journal:  Cell Prolif       Date:  2015-05-25       Impact factor: 6.831

3.  Major role of epidermal growth factor receptor and Src kinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells.

Authors:  Hong-Lin Chan; Hsiu-Chuan Chou; MaCarmen Duran; Jana Gruenewald; Michael D Waterfield; Anne Ridley; John F Timms
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

4.  Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study.

Authors:  Xiuwei Zhu; Xiaobo Zhou; Michael T Lewis; Ling Xia; Stephen Wong
Journal:  J Theor Biol       Date:  2010-10-20       Impact factor: 2.691

5.  Circadian Gating of the Mammalian Cell Cycle Restriction Point: A Mathematical Analysis.

Authors:  Jing Su; Michael A Henson
Journal:  IEEE Life Sci Lett       Date:  2015-07-13

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  A novel interaction between HER2/neu and cyclin E in breast cancer.

Authors:  E A Mittendorf; Y Liu; S L Tucker; T McKenzie; N Qiao; S Akli; A Biernacka; Y Liu; L Meijer; K Keyomarsi; K K Hunt
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

9.  Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis.

Authors:  Lydia Nakopoulou; Effie G Panayotopoulou; Ioanna Giannopoulou; Ioanna Tsirmpa; Sophia Katsarou; Eleni Mylona; Paraskevi Alexandrou; Antonios Keramopoulos
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

10.  CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.

Authors:  Emanuela Brunetto; Anna Maria Ferrara; Francesca Rampoldi; Anna Talarico; Elena Dal Cin; Greta Grassini; Lorenzo Spagnuolo; Isabella Sassi; Antonella Ferro; Lucia Veronica Cuorvo; Mattia Barbareschi; Sara Piccinin; Roberta Maestro; Lorenza Pecciarini; Claudio Doglioni; Maria Giulia Cangi
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.